序号 |
标题 |
次数 |
作者 |
发布时间 |
75376 |
MAL-di-EG-Val-Cit-PAB-MMAE,CAS编号:2746391-62-6 |
129 |
WYQ |
2024-12-19 |
75377 |
cas:644981-35-1 , Val-Cit-PAB-MMAE, ADC试剂 |
77 |
kx |
2024-12-19 |
75378 |
cas:2754384-60-4,DBCO-(PEG)3-VC-PAB-MMAE,抗体药物偶联物(ADC) |
153 |
kx |
2024-12-19 |
75379 |
AcLys-PABC-VC-Aur0101(CAS:1438851-17-2) |
110 |
WYQ |
2024-12-19 |
75380 |
反式环辛烯-MMAE,TCO-MMAE, ADC试剂 |
136 |
kx |
2024-12-19 |
75381 |
Hydrazone-doxorubicin,阿霉素-腙键偶联物 |
174 |
WYQ |
2024-12-19 |
75382 |
SPP-DM1(CAS号:452072-20-7)C44H59ClN4O14S2 |
147 |
WYQ |
2024-12-19 |
75383 |
氨基-二聚乙二醇-VG-N-双(一聚乙二醇-叠氮),Amino-PEG2-VG-N-Bis(PEG1-azide) |
71 |
kx |
2024-12-19 |
75384 |
DOTA-NHS ester,羟基琥珀酰亚胺-四氮杂环十二烷四乙酸(CAS号:170908-81-3) |
97 |
WYQ |
2024-12-19 |
75385 |
Maleimido-mono-amide-DOTA(CAS号:1006711-90-5) |
158 |
WYQ |
2024-12-19 |
75386 |
cas:2055041-40-0,Azido-PEG1-Val-Cit-PAB-OH,叠氮-一聚乙二醇-VAL-CIT-PAB-羟基 |
71 |
kx |
2024-12-19 |
75387 |
MB-VC-MGBA CAS号:932744-62-2 |
116 |
WYQ |
2024-12-19 |
75388 |
Anti-GPNMB-VC-MMAE-ADC抗体偶联药物 |
87 |
zyl |
2024-12-19 |
75389 |
MA-PEG8-VA-PAB-SG3199,硫醇反应SET™毒素 |
139 |
WYQ |
2024-12-19 |
75390 |
cas:1662687-83-3 , Mal-PEG2-Val-Cit-PABA,马来酰亚胺-二聚乙二醇-VAL-CIT-PABA |
80 |
kx |
2024-12-19 |
75391 |
Boc-Val-Ala-PAB cas:1884577-99-4 |
90 |
zyl |
2024-12-19 |
75392 |
perfluorophenyl 1-(cyclooct-2-ynyloxy)-2-oxo-6,9,12-trioxa-3-azapentadecan-15-oate |
74 |
wyh |
2024-12-19 |
75393 |
MA-PEG4-VA-PBD(CAS号:2259318-50-6) |
104 |
WYQ |
2024-12-19 |
75394 |
SPDP-Val-Cit-PAB-PNP-ADC抗体偶联药物 |
139 |
zyl |
2024-12-19 |
75395 |
cas:1438853-35-0,Mal-PEG3-Val-Cit-PAB-PNP,马来酰亚胺-三聚乙二醇-VAL-CIT-PAB-PNP 酯 |
73 |
kx |
2024-12-19 |
75396 |
Mc-vc-PABC-SP 141,一种用于抗体药物偶联物(ADC)合成的linker或连接臂 |
82 |
WYQ |
2024-12-19 |
75397 |
perfluorophenyl 1-(1,3-dioxoisoindolin-2-yloxy)-3,6,9,12-tetraoxapentadecan-15-oate |
107 |
wyh |
2024-12-19 |
75398 |
cas:2055041-37-5,Mal-PEG1-Val-Cit-PAB-OH,马来酰亚胺-一聚乙二醇-VAL-CIT-PAB-羟基 |
108 |
kx |
2024-12-19 |
75399 |
perfluorophenyl 15-(2,5-dioxo-2H-pyrrol-1(5H)-yl)-13-oxo-3,6,9-trioxa-12-azapentadecan-1-oate |
94 |
wyh |
2024-12-19 |
75400 |
MC-Val-Cit-PAB-PNP cas:159857-81-5 |
97 |
zyl |
2024-12-19 |
75401 |
NAMPT-linker(CAS号:2241019-57-6) |
80 |
WYQ |
2024-12-19 |
75402 |
cas:103848-61-9,6-Maleimidocaproic acid sulfo-NHS |
95 |
wyh |
2024-12-19 |
75403 |
cas:159857-80-4 ,MC-Val-Cit-PAB-OH, ADC(抗体偶联药物 ) |
102 |
kx |
2024-12-19 |
75404 |
Boc-Val-Cit cas:870487-08-4 |
128 |
zyl |
2024-12-19 |
75405 |
cas:663598-66-1,1-((4-((5-Nitropyridin-2-yl)disulfanyl)pentanoyl)oxy)-2,5-dioxopyrrolidine-3-sulfonic acid |
87 |
wyh |
2024-12-19 |
75406 |
cas:870487-10-8,Boc-Val-Cit-PAB-PNP,BOC-VAL-CIT-PAB-PNP 酯 |
92 |
kx |
2024-12-19 |
75407 |
cas:2353409-69-3 Mal-PEG8-Val-Cit-PAB-MMAE |
135 |
zyl |
2024-12-19 |
75408 |
cas:108852-90-0 Nemorubicin 奈莫柔比星 |
111 |
zyl |
2024-12-19 |
75409 |
cas:159858-22-7 , Fmoc-Val-Cit-PAB-OH,ADC(抗体偶联药物) |
74 |
kx |
2024-12-19 |
75410 |
cas:1626359-59-8 磺基-SPDB-DM4 |
81 |
zyl |
2024-12-19 |
75411 |
cas:870487-09-5,Boc-Val-Cit-PAB, ADC试剂 |
73 |
kx |
2024-12-19 |
75412 |
NH2-Glu-Gly-Cit-PAB-OH, ADC试剂 |
143 |
kx |
2024-12-19 |
75413 |
sulfo-SPDB-DGN462,用于提高化合物的水溶性和稳定性 |
129 |
WYQ |
2024-12-19 |
75414 |
Fmoc-Gly-Gly-Phe-Gly-OH, ADC试剂 |
105 |
kx |
2024-12-19 |
75415 |
1342211-31-7,MC-Val-Ala-OH,马来酰亚胺基己酰-L-缬氨酰-L-丙氨酸,ADC连接子多肽 |
132 |
kx |
2024-12-19 |
75416 |
MA-PEG4-VC-PAB-DMAE-PNU159682(CAS号:2259318-52-8) |
98 |
WYQ |
2024-12-19 |
75417 |
MC-vc-PAB-C6-a-amanitin,一种抗体药物偶联物(ADC) |
96 |
WYQ |
2024-12-19 |
75418 |
cas:690632-55-4,N-Succinimidyloxycarbonylpropyl Methanethiosulfonate |
62 |
wyh |
2024-12-19 |
75419 |
VC-MMAF(CAS号:863971-17-9) |
86 |
WYQ |
2024-12-19 |
75420 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin-ADC抗体偶联药物 |
82 |
zyl |
2024-12-19 |